These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31593308)

  • 1. Metformin Effects on FOXP3
    Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
    Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
    Curry J; Alnemri A; Philips R; Fiorella M; Sussman S; Stapp R; Solomides C; Harshyne L; South A; Luginbuhl A; Tuluc M; Martinez-Outschoorn U; Argiris A; Linnenbach A; Johnson J
    Laryngoscope; 2023 Aug; 133(8):1875-1884. PubMed ID: 36125263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I conventional dendritic cells and CD8
    Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
    Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin Clinical Trial in HPV+ and HPV- Head and Neck Squamous Cell Carcinoma: Impact on Cancer Cell Apoptosis and Immune Infiltrate.
    Curry JM; Johnson J; Mollaee M; Tassone P; Amin D; Knops A; Whitaker-Menezes D; Mahoney MG; South A; Rodeck U; Zhan T; Harshyne L; Philp N; Luginbuhl A; Cognetti D; Tuluc M; Martinez-Outschoorn U
    Front Oncol; 2018; 8():436. PubMed ID: 30364350
    [No Abstract]   [Full Text] [Related]  

  • 5. Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
    Curry J; Johnson J; Tassone P; Vidal MD; Menezes DW; Sprandio J; Mollaee M; Cotzia P; Birbe R; Lin Z; Gill K; Duddy E; Zhan T; Leiby B; Reyzer M; Cognetti D; Luginbuhl A; Tuluc M; Martinez-Outschoorn U
    Laryngoscope; 2017 Aug; 127(8):1808-1815. PubMed ID: 28185288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
    de la Iglesia JV; Slebos RJC; Martin-Gomez L; Wang X; Teer JK; Tan AC; Gerke TA; Aden-Buie G; van Veen T; Masannat J; Chaudhary R; Song F; Fournier M; Siegel EM; Schabath MB; Wadsworth JT; Caudell J; Harrison L; Wenig BM; Conejo-Garcia J; Hernandez-Prera JC; Chung CH
    Clin Cancer Res; 2020 Mar; 26(6):1474-1485. PubMed ID: 31848186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cell topography of head and neck cancer.
    Muijlwijk T; Nijenhuis DNLM; Ganzevles SH; Ekhlas F; Ballesteros-Merino C; Peferoen LAN; Bloemena E; Fox BA; Poell JB; Leemans CR; Brakenhoff RH; van de Ven R
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39053947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
    Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma.
    Kim CG; Hong MH; Kim D; Lee BH; Kim H; Ock CY; Kelly G; Bang YJ; Kim G; Lee JE; Kim C; Kim SH; Hong HJ; Park YM; Sim NS; Park H; Park JW; Lee CG; Kim KH; Park G; Jung I; Han D; Kim JH; Cha J; Lee I; Kang M; Song H; Oum C; Kim S; Kim S; Lim Y; Kim-Schulze S; Merad M; Yoon SO; Kim HJ; Koh YW; Kim HR
    Clin Cancer Res; 2024 May; 30(10):2097-2110. PubMed ID: 38457288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma.
    Shaban M; Raza SEA; Hassan M; Jamshed A; Mushtaq S; Loya A; Batis N; Brooks J; Nankivell P; Sharma N; Robinson M; Mehanna H; Khurram SA; Rajpoot N
    J Pathol; 2022 Feb; 256(2):174-185. PubMed ID: 34698394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic and Immunophenotypic Characterization of Tumor Immune Microenvironment in Squamous Cell Carcinoma of the Oral Tongue.
    Chatzopoulos K; Sotiriou S; Collins AR; Kartsidis P; Schmitt AC; Chen X; Khazaie K; Hinni ML; Ramsower CA; Zarka MA; Patel SH; Garcia JJ
    Head Neck Pathol; 2021 Jun; 15(2):509-522. PubMed ID: 33010009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.
    Bhattacharya S; Muhammad N; Steele R; Peng G; Ray RB
    Oncotarget; 2016 May; 7(22):33202-9. PubMed ID: 27120805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
    Liang Y; Lü W; Zhang X; Lü B
    Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
    Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
    Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.